TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04254133

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Complete questionnaire

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Complete questionnaire

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Provide saliva samples

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Provide saliva samples

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Intervention: Genetic Counseling
Description: Undergo counseling

Intervention type: OTHER
Intervention: Genetic Counseling
Description: Undergo counseling

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative Studies
Study: NCT04444063

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Incised Papilla Surgical Approach
Description: Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Incised Papilla Surgical Approach
Description: Horizontal or oblique incision is done on the buccal mucosa as far as possible from the marginal keratinized tissue and the inter dental papilla The horizontal/oblique incision is extended mesio-distally enough to allow proper visualization of the defect A full thickness flap is elevated apico- coronally to expose the coronal limit of the defect Scaling and root planning are done using mini-curettes and power driven ultrasonic tips with care trying to maintain fibers attached to the cementum Granulation tissue is removed with mini-curettes detached from the bony walls and removed from the base of the papilla carefully with microblades and microscissors .~1ry soft tissue closure will be performed by horizontal mattress suture 2mm from the edges of the incision as a first line of closure and then simple interrupted suture as a second line of closure using (5-0, 6-0) polypropylene suture.
Study: NCT04094610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral repotrectinib (TPX-0005)
Description: Oral repotrectinib (TPX-0005)
Study: NCT01220154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intraperitoneal Day 1 cycles 1-6 AUC
Study: NCT01933789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Feedback Form for Patients with Serious Illness
Description: The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately.
Study: NCT02757950

Intervention type: BIOLOGICAL
Intervention: Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
Description: Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.

Intervention type: BIOLOGICAL
Intervention: Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
Description: Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
Study: NCT00623584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal transplantation
Description: Full thickness penetrating keratoplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal transplantation
Description: Full thickness penetrating keratoplasty
Study: NCT00167466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soladey-3 toothbrush
Description: subject to brush with experimental Soladey-3 brush for 4 week

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Soladey-3 toothbrush
Description: subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
Study: NCT02710643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFATUMUMAB
Description: 8 weekly infusion of 1000 mg total dose
Study: NCT05719987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: After the endodontic procedure, Biodentine will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.

Intervention type: OTHER
Group type: OTHER
Intervention: MTA
Description: After the endodontic procedure, MTA will be placed into the apical portion of the canals. After 12 min, the coronal and middle third of the root canal will be filled with gutta-percha and AH Plus. The coronal restoration will be completed with GIC, composite, and stainless-steel crown.
Study: NCT01235871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB1578
Description: JAK2 Inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study: NCT02633852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Study: NCT03809793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: 12-week walking based intervention (3 sessions per week)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Program
Description: 12-week walking based intervention (3 sessions per week)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: DXA
Description: Participants will undergo an assessment of body composition (DXA)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: DXA
Description: Participants will undergo an assessment of body composition (DXA)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: used to measure fat stored in the liver

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: used to measure fat stored in the liver

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulinaemic Euglycaemic Clamp
Description: Participants will arrive at the laboratory after an overnight fast (\>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hyperinsulinaemic Euglycaemic Clamp
Description: Participants will arrive at the laboratory after an overnight fast (\>10 h) to undergo a Hyperinsulinaemic euglycaemic clamp to assess whole-body insulin sensitivity. Plasma glucose will be measured at regular intervals and muscle biopsies will be obtained from the vastus lateralis muscle of one leg before and after 2 hours of the clamp.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VO2 Max
Description: Assessment of maximum aerobic capacity.
Study: NCT01667315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0,375%
Description: Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
Study: NCT04201496

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
Description: Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks.
Study: NCT01220154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
Study: NCT04201496

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Description: Participants with be provided with Empagliflozin to take daily for approximately 10 weeks. Along with the study medication, participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks
Description: Participants will initially use the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Empaglizflozin will not be provided to this group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks
Description: Participants will initially use the Tandem t:slim insulin pump with Basal-IQ Technology for 2 weeks. Participants will then transition to using the Tandem t:slim insulin pump with Control-IQ Technology for 4 weeks. Empaglizflozin will not be provided to this group.
Study: NCT01687231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-neutropenic Diet
Description: Non-neutropenic diet is without restriction.
Study: NCT00336492

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
Study: NCT02340104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: 4 milligrams (mg) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^13C4D3^15N]-baricitinib
Description: 4 micrograms (μg) administered intravenously (IV)
Study: NCT00915902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acid ethyl esters
Description: Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
Study: NCT01033396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: PF-03654764 single dose 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allegra
Description: Fexofenadine single dose 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03654764
Description: PF-03654764 single dose 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allegra-D
Description: Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
Study: NCT03321617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Study: NCT01033396

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo single dose
Study: NCT03321617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
Study: NCT02688010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise reduction and cycled light
Description: Reduced noise exposure (sound levels \<45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
Study: NCT04635501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABS 5.6.7
Description: Patients whose access site will be closed with the ABS 5.6.7
Study: NCT02818075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Phone Based Peer Support
Description: Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
Study: NCT02080130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
Study: NCT04089124

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery of zone II cut flexor repair
Description: we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery of zone II cut flexor repair
Description: we will repair tendon of FDP only using 6 strand technique using PDS 4/0 core suture - prolene 6/0 running suture
Study: NCT01267435

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior cruciate ligament reconstruction
Description: reconstruct the anterior cruciate ligament rupturing
Study: NCT01569204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Study: NCT00985439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (lower dose)
Description: 18-mg Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Test (upper dose)
Description: 35-mg Single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 400 mg
Description: Capsules 2 x 200 mg Single-dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules 2 Single-dose
Study: NCT01929486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
Study: NCT02294981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Excimer laser phototherapy
Description: Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer laser phototherapy
Description: Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
Study: NCT01152645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ 197
Description: Orally twice daily administration of ARQ 197
Study: NCT02167659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 23-32 mmHg compression sleeve with gauntlet
Description: A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 23-32 mmHg compression sleeve with gauntlet
Description: A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.
Study: NCT02080130

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics combination
Description: LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02937259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient self-admission to inpatient treatment
Description: Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
Study: NCT01569204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study: NCT03643991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted Blanket
Description: Weighted blanket will be given to patients based on the patient weight (10% of patients body weight) for three nights while on inpatient unit.
Study: NCT01569204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procarbazine
Study: NCT02562040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (eAT)
Description: Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
Study: NCT01569204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brentuximab Vedotin
Study: NCT00427661

Intervention type: OTHER
Group type: OTHER
Intervention: Busulfan; Fludarabine; cyclosporine A and MMF
Description: Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
Study: NCT03758924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAVEX2-73
Description: Liquid oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid oral solution
Study: NCT01117597

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low RF exposure level
Description: Exposure with 1.5 W/kg

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: sham exposure
Description: intervention with sham RF exposure

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: high RF exposure
Description: intervention with high RF exposure